A Phase 2 interventional study of Culturelle 10 Billion CFU Capsule (2 doses) and Culturelle 10 Billion CFU Capsule (4 doses) in Spinal Cord Injuries and Neurogenic Bladder, sponsored by Medstar Health Research Institute. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Medstar Health Research Institute · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 968 studies in Spinal Cord Injuries with a site in United States — 249 open to participants now, 308 under way, 7 of them phase 3. Spinal Cord Injuries · United States.
Among the 968 studies in Spinal Cord Injuries with a site in United States, this one is the 39th largest by enrollment of the 836 interventional ones that give a count, is one of 47 that started in 2020, is one of 77 in phase 2, and was the 557th registered.
2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.
Browse Spinal Cord Injuries studies →249 of the 968 studies in Spinal Cord Injuries with a site in United States are open now. Recruiting first, the newest first:
Medical University of South Carolina · Sites in United States
Ages 18–70
Johns Hopkins University · Sites in United States
Ages 18–80
University of Miami · Sites in United States
Ages 22–70
Kessler Foundation · Sites in United States
Ages 22+
Neuralink Corp · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
968 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 94 · Phase 2 132 · Phase 3 39 · Phase 4 27
First in 1986; this study’s year is marked. 47 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 182 is above the median of 24 across 1,639 interventional studies indexed under Spinal Cord Injuries.
Median enrollment 24 across the 836 interventional studies, 58 across the 128 observational. Of the 576 that completed or were terminated, 225 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 968 have an industry lead sponsor. The 10 most frequent:
Medstar Health Research Institute is the lead sponsor of 162 studies on the registry; 32 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 7 (50%) have results posted.
Medstar Health Research Institute has 8 studies filed under Spinal Cord Injuries — fewer than ten, so there is no comparison to draw.
117 of the studies in Spinal Cord Injuries with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05903859Phase 3University of MiamiImprovement of Reproductive Function in Men With Spinal Cord Injury (SCI) | 2027-05-31 |
| NCT07625332Phase 3Northwell HealthPilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI) | 2027-08 |
| NCT03930056Shirley Ryan AbilityLabC-Brace II Spinal Cord Injury | 2026-11 |
| NCT04077346University of LouisvilleNeuromodulation of Spinal Locomotor Circuitry to Elicit Stepping After Pediatric Spinal Cord Injury | 2026-11 |
| NCT05423600Virginia Commonwealth UniversityTransspinal Stimulation With and Without Blood Flow Restricted Exercise Via Telehealth in Persons With Tetraplegia | 2026-11 |
Add all 117 to your calendar (.ics) → With an account.
Among the 968 studies in Spinal Cord Injuries with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objectives of the proposed research among this population are: 1) to define clinically meaningful change (i.e. differentiating states of health and illness) with respect to urinary symptoms, urine inflammation, cultivable bacteria, and the urine ecosystem; and 2) to determine the optimal intravesical Lactobacillus RhamnosusGG (LGG®) dose to be used to reduce urinary symptoms in a future clinical trial.
Urinary tract infection (UTI) is the most common outpatient infection world-wide, and for people with spinal cord injury (SCI) and neurogenic bladder (NB), it is the most common infection, secondary condition, cause for emergency room visits, and infectious cause of hospitalization. Despite its prevalence, attempts to ameliorate UTI among people with SCI are stymied by long-standing diagnostic challenges which arise from evidence gaps around "gold standard" diagnostic tests (urinalysis and urine culture) that have lower sensitivity and specificity for UTI in this population. A high prevalence of chronic inflammation leading to persistence of white blood cells (WBC) in the urine confounds the utility of WBC count, pyuria, and leukocyte esterase as biomarkers for UTI; nitrites in urine indicate the presence of only specific (but not all) organisms, many of which are present to a greater extent in the urine of people with SCI; and people with SCI have a high prevalence of asymptomatic bacteriuria. These physiologic changes render the gold standard diagnostic tests less useful for identifying UTI in persons with SCI.
SPECIFIC AIM 1
2 urine samples (sampling at least 2 weeks apart) for urinalysis, urine culture, uNGAL, and NGS (16S rRNA and shotgun) under the same conditions. In addition to completing the USQNB-IC prior to urine collection, participants will complete the USQNB-IC 3 days after urine collection
SPECIFIC AIM 2 Intravesical LGG dose (group: high or low) will be obtained, USQNB-IC, urine collection for urinalysis, culture, NGAL and next generation sequencing as described above. And patient satisfaction questions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the intermittent catheter. Participants will receive 2 LGG capsules and will repeat this process the following day ("Low" dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (2 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion.
Drug: Culturelle 10 Billion CFU Capsule (2 doses)
For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the intermittent catheter. Participants will receive 4 LGG capsules and will repeat this process the following day twice for a total of four doses ("High" dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (4 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion.
Drug: Culturelle 10 Billion CFU Capsule (4 doses)
For the LGG instillation, participants will be instructed to mix the contents of 1 LGG capsule into saline. After mixing, participants will draw up the liquid LGG mixture into a syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 2 LGG capsules and will repeat this process the following night ("Low" dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (2 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining capsules
Also known as: Lactobacillus RhamnosusGG
For the LGG instillation, participants will be instructed to mix the contents of 1 LGG capsule into saline. After mixing, participants will draw up the liquid LGG mixture into a syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 4 LGG capsules and will repeat this process twice daily for a total of four doses ("High" dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (4 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining capsules
Also known as: Lactobacillus RhamnosusGG
Number of Participants With Successful Reduction of Urinary Symptoms
20% reduction in urinary symptoms within 48 hours of completion of intervention
Time frame: Participants (low and high group) fill out the USQNB-IC at the onset of their symptoms, and 48 hours after the last dose. Definition of "success" is 20% reduction in number of endorsed symptoms between the first and final USQNB-IC.
Leukocyte Esterase
urinary leukocyte esterase level (ordinal count levels)
Time frame: Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 36 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.
Change in Cultivable Bacteria Pre and Post LGG Instillations
Standard urine culture (SUC) results based on quantity (colony forming units) and identified organism. (number of organisms cultivated/identified; yes/no if any were cultivated at or greater than 10\^5)
Time frame: Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 24 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.
Change in Urine Nitrite Pre and Post LGG Instillations
Standard urine analysis. Urine derived nitrites (positive or negative)
Time frame: Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 24 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.
Change in Urine White Blood Cell Count Pre and Post LGG Instillations
urine derived white blood cells per high powered field (ordinal count levels)
Time frame: Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 24 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.
Change in uNGAL Pre and Post LGG Instillations
urinary neutrophil gelatinase-associated lipocalin in µg/L (continuous)
Time frame: Participants in our two dose groups, low (two doses 24 hours apart) and high (four doses 24 hours apart), give a urine sample at the onset of their symptoms, and then again 48 hours after the last dose.
Participants were recruited nationwide
| Milestone | Low Dosage Group | High Dosage Group |
|---|---|---|
| Started | 89 | 88 |
| Completed | 61 | 58 |
| Not completed | 28 | 30 |
20% reduction in urinary symptoms within 48 hours of completion of intervention
| Participants | Low Dosage Group | High Dosage Group |
|---|---|---|
| Number of Participants With Successful Reduction of Urinary Symptoms | 30 | 28 |
urinary leukocyte esterase level (ordinal count levels)
| participants | Low Dosage Group | High Dosage Group |
|---|---|---|
| Unchanged LE | 12 | 13 |
| Worsened LE | 2 | 1 |
| Improved LE | 0 | 1 |
Standard urine culture (SUC) results based on quantity (colony forming units) and identified organism. (number of organisms cultivated/identified; yes/no if any were cultivated at or greater than 10\^5)
| 10^5 colony forming units | Low Dosage Group | High Dosage Group |
|---|---|---|
| Change in Cultivable Bacteria Pre and Post LGG Instillations | .1429 ± .53452 | -.0769 ± .95407 |
Standard urine analysis. Urine derived nitrites (positive or negative)
| participants | Low Dosage Group | High Dosage Group |
|---|---|---|
| Unchanged Nitrite | 11 | 11 |
| Improved Nitrite | 1 | 1 |
| Worsened Nitrite | 2 | 3 |
urine derived white blood cells per high powered field (ordinal count levels)
| Participants | Low Dosage Group | High Dosage Group |
|---|---|---|
| Unchanged WBC | 10 | 11 |
| Worsened (pyuria developed) | 4 | 4 |
urinary neutrophil gelatinase-associated lipocalin in µg/L (continuous)
| µg/L value | Low Dosage Group | High Dosage Group |
|---|---|---|
| Change in uNGAL Pre and Post LGG Instillations | 143.9484 ± 466.54514 | 10.3927 ± 117.07663 |
Collected over 4 years, 7 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Low Dosage Group | 1/89 (1.1%) | 5/89 (5.6%) | 9/89 (10.1%) |
| High Dosage Group | 2/88 (2.3%) | 10/88 (11.4%) | 12/88 (13.6%) |
| Event | Low Dosage Group | High Dosage Group |
|---|---|---|
| UTIRenal and urinary disorders | 3/89 | 3/88 |
| UTI and COVIDRenal and urinary disorders | 0/89 | 1/88 |
| Bilaterial Lower Extremity amputationSurgical and medical procedures | 0/89 | 1/88 |
| CellulitisSkin and subcutaneous tissue disorders | 0/89 | 1/88 |
| Septic shockRenal and urinary disorders | 0/89 | 1/88 |
| Blood in catheterRenal and urinary disorders | 0/89 | 1/88 |
| Prolapsed ostomySurgical and medical procedures | 0/89 | 1/88 |
| DeathGeneral disorders | 0/89 | 1/88 |
| Food infectionInfections and infestations | 1/89 | 0/88 |
| Back PainGeneral disorders | 1/89 | 0/88 |
| Event | Low Dosage Group | High Dosage Group |
|---|---|---|
| Increase in urinary symptomsRenal and urinary disorders | 0/89 | 7/88 |
| UTIRenal and urinary disorders | 5/89 | 3/88 |
| Rash on handGeneral disorders | 0/89 | 1/88 |
| Catheter tip syring not fitting the catheterRenal and urinary disorders | 0/89 | 1/88 |
| AnxietyPsychiatric disorders | 1/89 | 0/88 |
| HeadacheGeneral disorders | 1/89 | 0/88 |
| burning while instillingRenal and urinary disorders | 1/89 | 0/88 |
| Blood coming out around catheterInfections and infestations | 1/89 | 0/88 |
| Back painGeneral disorders | 1/89 | 0/88 |
Analyze results low dosage group compared to high dosage group. Both groups consists of individuals with neurogenic lower urinary tract dysfunction (spinal cord injury, spina bifida, multiple sclerosis), using intermittent catheterization for bladder management.
| Age, Continuous(years) | Low Dosage Group | High Dosage Group | Total |
|---|---|---|---|
| Mean | 50 (22 to 75) | 47 (18 to 73) | 49 (18 to 75) |
| Sex: Female, Male(Participants) | Low Dosage Group | High Dosage Group | Total |
|---|---|---|---|
| Female | 37 | 43 | 80 |
| Male | 52 | 45 | 97 |
| Ethnicity (NIH/OMB)(Participants) | Low Dosage Group | High Dosage Group | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 2 | 8 |
| Not Hispanic or Latino | 83 | 86 | 169 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Low Dosage Group | High Dosage Group | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 2 | 2 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 19 | 13 | 32 |
| White | 66 | 69 | 135 |
| More than one race | 2 | 3 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Low Dosage Group | High Dosage Group | Total |
|---|---|---|---|
| United States | 89 | 88 | 177 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2020 to primary completion in Feb 2025, 56 months.
Results were first posted in Nov 2026, 1 year 8 months after primary completion.
Of 44 non-industry phase 2 interventional studies under Spinal Cord Injuries, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 64. This study's 56 months is above that.
Counting every sponsor, half of 49 studies reached it within 46 months; a quarter within 28 and three quarters within 64.
Start moved once since we started tracking on Sep 25, 2026: May 2020 → Jun 2020, on Nov 3, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medstar Health Research Institute →